Precision medicine (also known as personalized medicine) uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat cancer. Precision medicine includes the use of biomarkers, molecular testing, and targeted therapies to deliver a personalized approach to cancer therapy through the use of molecular and genomic information about individual cancers. The National Cancer Institute (NCI) defines precision medicine as “discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.”
As the precision medicine landscape evolves, ACCC supports the multidisciplinary cancer care team with education in the following areas:
Enabling Innovation: Testing for KRAS G12C in NSCLC
Bringing CAR T-Cell Therapies to Community Oncology
Eliminating Precision Medicine Disparities
Integration of MRD Testing: A Pathway for Patients with B-Cell Acute Lymphoblastic Leukemia
Integration of Pathology with the Cancer Care Team
Quality Improvement in Breast Cancer Through BRCA Testing
Operational Pathways for Molecular Testing in NSCLC
Preparing Community Providers for Bispecific Antibodies
Part of the Biomarker101 webinar series, Pathology 101 addresses the role of laboratory medicine professionals and pathologists in biomarker testing, incorporating a review of testing techniques and applications, lab-specific regulations, and the impact of those regulations on biomarker testing.
Genetic Testing and Implementation of Cancer Genomics in Clinical Care was part of the Oncology State Societies at ACCC Virtual Symposium on Friday, November 13, 2020.
Clinical updates on MRD testing for Chronic Lymphocytic Leukemia (CLL) and the importance of incorporating it into the treatment plan.
We will review current policies and regulations that drive costs related to biomarker testing.
Deep dive into the differences between germline and somatic mutations, with case examples, and presentation of findings from the LUNGevity/FORCE patient survey.
Introduction to cancer biomarkers, relevant terminology, and implications for cancer care.
Learn about the current clinical applications of liquid biopsies, associated reimbursement issues, and what you can do to implement these tests at your program.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
NCCN Policy Report: Developments in Molecular Testing and Biosimilars (requires login)
Winckworth-Prejsnar K, Nardi EA, Lentz L, et al. NCCN Policy Report: Developments in Molecular Testing and Biosimilars. J Natl Compr Cancer Netw. 2017;15(6):772-782.
Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine
Craig LA, Phillips JK, Moses HL. (eds.) Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine. Washington, DC: National Academies Press; 2016.
ACCC and CAP TODAY webinar: CAP/AMP/IASLC Guidelines for NSCLC: Current Experience and Future Update Four national thought-leaders examine current guidelines, planned updates, and provide expert feedback on the impact of these guidelines on practices.
This webinar was originally broadcast on Nov. 30, 2016.